In push to expand its CAR-T therapies to US, China biotech Oricell raises additional $45M
Shanghai biotech Oricell has raised an additional $45 million to bankroll its preclinical and early-stage cancer cell therapies, it announced Tuesday morning.
Following a showing at ASCO last year with a GPRC5D-directed CAR-T therapy for multiple myeloma, Oricell raised a $120 million Series B in July. The latest raise is an extension of that round, and was led by RTW Investments and Qatar Investment Authority, followed by existing investors Qiming Venture Partners and C&D Emerging Industry Equity Investment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.